Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Drugs In Development, 2021

December 2021 | 58 pages | ID: L8E11C565413EN
Global Markets Direct

Abstracts

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Drugs In Development, 2021

SUMMARY

According to the recently published report 'Leptin Receptor – Drugs In Development, 2021'; Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) pipeline Target constitutes close to 11 molecules.

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) – Leptin receptor or LEP-R is a protein encoded by the LEPR gene. It acts as a receptor for hormone LEP/leptin. Upon binding it mediates LEP central and peripheral effects through the activation of different signaling pathways such as JAK2/STAT3 and MAPK cascade. LEP acts as an appetite-regulating factor that induces a decrease in food intake and an increase in energy consumption by inducing anorexinogenic factors and suppressing orexigenic neuropeptides also regulates bone mass and secretion of hypothalamo-pituitary-adrenal hormones. In the periphery increases basal metabolism, influences reproductive function, regulates pancreatic beta-cell function and insulin secretion, is pro-angiogenic and affects innate and adaptive immunity.

The report 'Leptin Receptor – Drugs In Development, 2021' outlays comprehensive information on the Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 2 and 9 respectively. Report covers products from therapy areas Metabolic Disorders, Oncology, Central Nervous System and Ophthalmology which include indications Obesity, Lipodystrophy (Lipoatrophy), Triple-Negative Breast Cancer (TNBC), Acquired Generalized Lipodystrophy (Lawrence Syndrome), Alzheimer's Disease, Choroidal Neovascularization, Congenital Generalized Lipodystrophy (Berardinelli-Seip Syndrome), Insulin Resistance, Solid Tumor, Type 1 Diabetes (Juvenile Diabetes) and Type 2 Diabetes.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape forLeptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)
• The report reviews Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics and enlists all their major and minor projects
• The report assesses Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Overview
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Companies Involved in Therapeutics Development
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Drug Profiles
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Dormant Products
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Discontinued Products
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Allysta Pharmaceuticals Inc, 2021
Pipeline by Amryt Pharma Plc, 2021
Pipeline by Arrevus Inc, 2021
Pipeline by Astellas Pharma Inc, 2021
Pipeline by Cellivery Therapeutics Inc, 2021
Pipeline by Jyant Technologies Inc, 2021
Pipeline by NeuroNano Pharma Inc, 2021
Pipeline by Neurotez Inc, 2021
Pipeline by Regeneron Pharmaceuticals Inc, 2021
Pipeline by XL-protein GmbH, 2021
Dormant Projects, 2021
Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021